Targeted Therapy in Advanced Bladder Cancer
Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years….
Surgical Advances in Bladder Cancer
Bladder cancer is the most expensive cancer to treat from diagnosis to death. Frequent disease recurrence, intense follow-up, and expensive, invasive techniques for diagnosis and treatment drive these costs for…
Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer
Since the advent of cisplatin-based combination therapy in the management of muscle-invasive and advanced bladder cancer, there has been little progress in improving outcomes for patients. Novel therapies beyond cytotoxic…
Novel Biomarkers to Predict Response and Prognosis in Localized Bladder Cancer
This review summarizes recent developments in diagnostic and prognostic biomarkers for nonmuscle invasive bladder cancer (NMIBC). Although the number of new biomarkers increases continuously, none are included in practice guidelines….
Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer
The Cancer Genome Atlas project has identified and confirmed several important molecular alterations that form the basis for tumorigenesis and disease progression in muscle-invasive bladder cancer. Profiling studies also have…
Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy
Improvements in the accuracy of clinical staging and refinements in patient selection may allow for improved outcomes of bladder-preservation strategies for muscle-invasive bladder cancer incorporating radical transurethral resection (TUR) and…
Neoadjuvant Chemotherapy in the Management of Muscle-Invasive Bladder Cancer
Although cisplatin-based chemotherapy followed by radical cystectomy is the standard treatment of muscle-invasive bladder cancer, population-based studies reveal that only a small fraction of patients actually receive such treatment. A…
Novel Therapeutic Approaches for Recurrent Nonmuscle Invasive Bladder Cancer
This article summarizes strategies being investigated in patients with nonmuscle invasive bladder cancer. Progress has been made toward improving the delivery method of intravesical agents. Intravesical therapy is limited by…
Trimodality Therapy in Bladder Cancer
Radical cystectomy is a standard treatment of nonmetastatic, muscle-invasive bladder cancer. Treatment with trimodality therapy consisting of maximal transurethral resection of the bladder tumor followed by concurrent chemotherapy and radiation…
Advances in Imaging Technologies in the Evaluation of High-Grade Bladder Cancer
Bladder cancer ranges from a low-grade variant to high-grade disease. Assessment for treatment depends on white light cystoscopy, however because of its limitations there is a need for improved visualization…
